Evidence Snapshot

Interleukin-1 receptor-associated kinase 1

CHEMBL3357 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:09:36Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 5:09 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL3357

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Interleukin-1 receptor-associated kinase 1 as ChEMBL target CHEMBL3357, mapped to UniProt P51617. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Interleukin-1 receptor-associated kinase 1

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL3357

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P51617

Interleukin-1 receptor-associated kinase 1

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Interleukin-1 receptor-associated kinase 1 matters

As of 2026-09-13

Interleukin-1 receptor-associated kinase 1 is reviewed as Interleukin-1 receptor-associated kinase 1 (UniProt P51617); Interleukin-1 receptor-associated kinase 1 shows approved-linked disease relevance led by polycythemia vera. 1 more disease program remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 25 approved drugs, 1890 compounds, and 345 assays, with lead potency reaching pChEMBL 8.7.

Protein context

Interleukin-1 receptor-associated kinase 1

Interleukin-1 receptor-associated kinase 1 Sequence length is 712 aa.

Review this target as Interleukin-1 receptor-associated kinase 1, mapped to UniProt P51617. Sequence length is 712 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P51617 Protein

Disease context

polycythemia vera

Interleukin-1 receptor-associated kinase 1 shows approved-linked disease relevance led by polycythemia vera. 1 more disease program remain visible in the same review block. 1 linked drug keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include PACRITINIB CITRATE.

Start review with polycythemia vera because it currently carries approved-linked support. Linked drugs include PACRITINIB CITRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 1 linked drug

Activity base

Portfolio and assay base

ChEMBL currently tracks 25 approved drugs, 1890 compounds, and 345 assays for this target. The dominant activity type is KI. CHEMBL5283628 is the current potency anchor at pChEMBL 8.7.

Use CHEMBL5283628 as the tractability anchor when discussing potency (pChEMBL 8.7).

Activity source · ChEMBL 36 via Core Engine

25 approved pChEMBL 8.7

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Interleukin-1 receptor-associated kinase 1 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P51617, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why polycythemia vera is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1890

Total Compounds

345

Total Assays

Approved Drugs

IC50: 588.0, KI: 626.0, KD: 342.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5283628	8.7	IC50	—
No preferred name CHEMBL5927784	8.5	Kd	—
No preferred name CHEMBL6002371	8.5	Kd	—
No preferred name CHEMBL5949720	8.3	IC50	—
No preferred name CHEMBL2172315	8.2	Kd	—

Approved Drugs

Structure	Compound	First Approval
	QUIZARTINIB CHEMBL576982	2023
	PACRITINIB CHEMBL2035187	2022
	FEDRATINIB CHEMBL1287853	2019
	ENCORAFENIB CHEMBL3301612	2018
	ABEMACICLIB CHEMBL3301610	2017
	NINTEDANIB CHEMBL502835	2014
	AFATINIB CHEMBL1173655	2013
	AFATINIB DIMALEATE CHEMBL2105712	2013
	BOSUTINIB CHEMBL288441	2012
	PONATINIB CHEMBL1171837	2012
	CRIZOTINIB CHEMBL601719	2011
	RUXOLITINIB CHEMBL1789941	2011
	SUNITINIB CHEMBL535	2006
	GEFITINIB CHEMBL939	2003

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:09:36Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 5:09 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL3357